By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
October 31, 2025 4:46 AM EDT
Medical Herald
Search
  • Health Conditions
    Health ConditionsShow More
    Beware of Counterfeit Weight Loss Drugs Sold Online
    Weight Management
    Father’s Back Pain Leads to Tragic Cancer Diagnosis
    Cancer
    Novo Nordisk’s CEO Emphasizes Strategic Risks to Lead Obesity Market
    Weight Management
    Medtronic Launches Ankle Implant for Bladder Control
    Health Conditions
    Stewart’s Caring Place Highlights All Cancer Awareness in October
    Breast Cancer
  • Wellness & Self-Care
    Wellness & Self-CareShow More
    Pureance HydraLift: A Scientific Approach to Hair Care
    Wellness & Self-Care
    Jewel Reflects on Fame and Mental Health Advocacy Journey
    Mental Health
    Discover the Health Benefits of Hazelnuts
    Healthy Living
    How the Government Shutdown Affects Health Insurance Costs
    Wellness & Self-Care
    NYC Sues Tech Giants Over Youth Mental Health Crisis
    Mental Health
  • Nutrition & Fitness
    Nutrition & FitnessShow More
    Delicious Roasted Salmon with Olives from Dan Pelosi
    Healthy Recipes
    Short Exercise Bursts: A New Trend in Fitness?
    Fitness
    PepsiCo Launches Protein-Focused Beverages to Meet Demand
    Diet & Nutrition
    Calcium Loaf: A Depression-Era Recipe for Today’s Food Challenges
    Healthy Recipes
    Effective Full-Body Workout Enhances Testosterone and Muscle
    Fitness
  • Innovation
    InnovationShow More
    Understanding Superspreading and Pathogen Virulence Evolution
    Innovation
    Starkey Launches Innovative AI Hearing Aid for All Generations
    Innovation
    AstraZeneca Boosts Virginia Investment to $4.5 Billion for Drug Production
    Drugs & Medications
    How ALV-J Virus Bypasses Immune Defense Using miR-155
    Innovation
    Nursing Homes’ Use of Painkillers and Antidepressants Raises Risks
    Drugs & Medications
  • News
    NewsShow More
    Diet Coke Lime Set to Return in 2025 After Seven-Year Hiatus
    News
    Dublin Environmentalists Celebrate Tentative Repeal of Measure II
    News
    Trust in CDC Plummets Under Kennedy’s Leadership, Poll Reveals
    News
    St. Joseph Plans New Community Center and Cannabis Dispensary
    News
    Harry and Meghan Shine at World Mental Health Day Gala in NYC
    News
Font ResizerAa
Medical HeraldMedical Herald
  • Health Conditions
  • Wellness & Self-Care
  • Nutrition & Fitness
  • Innovation
  • News
Search
  • Health Conditions
  • Wellness & Self-Care
  • Nutrition & Fitness
  • Innovation
  • News
Follow US
Copyright © 2025, Medical Herald. All Rights Reserved.
Home » Innovation » Drugs & Medications » Skye Bioscience’s Weight Loss Drug Underwhelms in Phase 2 Trial

Skye Bioscience’s Weight Loss Drug Underwhelms in Phase 2 Trial

By Ethan Granger
Published: October 8, 2025
Share

Skye Bioscience Inc. (NASDAQ:SKYE) experienced a significant drop in its stock price on Monday following the release of disappointing results from its Phase 2a CBeyond proof-of-concept study on nimacimab, an investigational drug for weight loss.

The company reported that the nimacimab monotherapy did not meet its primary goal of achieving weight loss as compared to the placebo group, with weight loss results of -1.52% versus -0.26% for placebo based on the modified Intent-to-Treat (mITT) analysis. This lack of efficacy has raised concerns about the drug’s viability in the competitive obesity treatment market.

Preliminary analyses also indicated that nimacimab exposure levels were lower than anticipated, suggesting the need for further evaluation of higher doses. Despite these setbacks, data from the combination group involving 200 mg of nimacimab and the diabetes medication semaglutide showed more promising results. In this cohort, patients experienced a significant weight loss of -13.2%, compared to -10.25% with semaglutide alone, with a statistically significant p-value of 0.0372.

Notably, the weight loss observed in the combination therapy did not plateau over the 26 weeks of the study, indicating sustained effectiveness. This outcome paves the way for potential future studies focusing on the combinations of nimacimab with incretin-based therapies, which include semaglutide, an active ingredient in Novo Nordisk’s (NYSE:NVO) popular weight loss medications Wegovy and Ozempic.

In terms of safety, the combination therapy showcased a favorable profile with tolerability akin to that of placebo treatments. There was no increase in gastrointestinal (GI) adverse events reported when nimacimab was used with semaglutide, as well as no noted rise in neuropsychiatric side effects.

The data also revealed impressive results in a per-protocol analysis where all patients in the combination therapy group achieved more than 5% weight loss, while this figure stood at 85% for those receiving semaglutide alone. Furthermore, 67% of patients in the combination group lost over 10% of their weight, versus 50% for semaglutide alone.

Additionally, an improvement in the lean mass to fat ratio was observed by Week 26. Participants in the nimacimab and semaglutide combination group exhibited a ratio of 0.26, compared to 0.02 in the placebo group and 0.13 in the semaglutide-only group.

The safety profile for nimacimab as a monotherapy was reassuring, showing tolerability similar to placebo with no increase in GI adverse events. Among the safety analysis population, rates of GI issues were 27% for nimacimab alone, slightly lower than the 29.5% seen with the placebo. When combining with semaglutide, GI adverse event rates were 57.1% compared to 66.7% for semaglutide alone, indicating a better safety outcome.

Importantly, no neuropsychiatric issues were identified, and there were no increases in symptoms of anxiety, insomnia, or depression among patients taking nimacimab, whether as monotherapy or in combination.

Despite some positive findings in combination therapy, the overall discontinuation rate for the CBeyond study was notable at 27%. Many of these discontinuations were attributed to adverse events, with the placebo group accounting for 60% of these cases, raising valid discussions about the overall credibility of the results concerning the standalone nimacimab treatment.

As a result of the unfavorable news, Skye Bioscience’s stock plummeted significantly, down 60% to $1.90 during premarket trading on Monday. Investors will be keenly watching how the company handles this setback and any potential future developments regarding nimacimab and its positioning in the obesity treatment landscape.Drugs & Medications

TAGGED:Skye BioscienceWeight Loss Drug
Share This Article
Facebook LinkedIn Email Copy Link
Leave a Comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

HOT NEWS

Diet Coke Lime Set to Return in 2025 After Seven-Year Hiatus

October 30, 2025

Understanding Superspreading and Pathogen Virulence Evolution

Superspreading alters how pathogens evolve, influencing virulence, transmission, and long-term epidemic behavior across diverse host…

October 30, 2025

Dublin Environmentalists Celebrate Tentative Repeal of Measure II

A judge ruled Dublin must conduct an environmental review of Measure II, a controversial plan…

October 30, 2025

Delicious Roasted Salmon with Olives from Dan Pelosi

Dan Pelosi’s roasted salmon with Castelvetrano olives and orange zest blends freshness, simplicity, and flavor…

October 30, 2025

YOU MAY ALSO LIKE

Study Questions Tramadol’s Effectiveness for Chronic Pain Relief

A new study reveals tramadol provides limited relief and higher risks, challenging its role as a safe opioid for managing…

October 13, 2025

More Americans Seek Unregulated GLP-1 Drugs Amid Shortages

FDA warns of growing risks from gray-market GLP-1 drugs as unregulated Ozempic and Wegovy alternatives raise safety and counterfeit concerns.

October 13, 2025

GLP-1 Drugs May Lower Cancer Risk for Women, Study Shows

GLP-1 drugs show promise in lowering cancer risks for women, while also improving obesity, fertility, and overall health outcomes.

October 3, 2025

Covid Booster Shots: Are They Necessary for Younger Adults?

A VA study shows Covid vaccines reduce deaths by 64%, proving especially vital for those over 65 while offering modest…

October 21, 2025

Medical Herald is your trusted source for medical news, scientific research, health policy updates, and expert insights from around the world. 

Category

  • Health Conditions
  • Wellness & Self-Care
  • Nutrition & Fitness
  • Innovation
  • News
  • Privacy Policy
  • About Us
  • Contact

Follow US: 

  • Grow Big Agency Sites:
  • London Business Journal
Copyright © 2025, Medical Herald. All Rights Reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?